Abstract
Background
The cholecystokinin receptor type 2 (CCK-2R) is overexpressed in MTC with very high density and incidence over 90%, as revealed by autoradiographic studies [1] . According to these findings suitable tracers for targeting this particular receptor were developed. From the late 90s last century, a variety of CCK-2/gastrin related peptides (members of the gastrin-and cholecystokinin families, or possessing characteristics of both), were radiolabelled and studied in vitro (in terms of proper peptide sequence synthesis, stability
Original of the compound in serum, receptor affinity and binding) and in preclinical animal models (in terms of biodistribution, excretion pathways and uptake ratios in tumour to various organs) [2] [3] [4] [5] [6] [7] [8] . Some of these radiopeptides were tested in small clinical pilot-studies in humans. Receptor targeting was seen to some extent in physiologically CCK-2/gastrin receptor expressing tissues and most importantly, in the tumour tissue with the high tumour to background ratios. In the attempt to enable therapy with CCK-2/gastrin receptor-binding radiolabelled analogues further research was stimulated and coordinated within the European COST BM0607 project. Novel analogues were synthetized and comparatively evaluated both in vitro as well as in vivo regarding stability, receptor binding and tumour targeting [3] [4] [5] [6] [7] [8] . As a result of these comparisons one derivative, namely DOTA-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-G lu-Trp-Met-Asp-Phe-NH 2 (CP04, Fig. 1 ) showed the most promising characteristics in terms of high stability and receptor affinity, high and persistent tumour uptake and low kidney retention. Therefore, 111 In-CP04 was selected for further clinical evaluation [9] .
The gastrin and CCK-2 receptors are potential targets for radionuclide therapies, because ligands such as CP04 can be radiolabelled with 111 In or 68 Ga for imaging, or with 90 Y and 177
Lu for therapy.
Recently, the influence of 111 In-radiolabelled DOTA-minigastrin analogues stereochemistry on their in vitro and in vivo behaviour was evaluated [10] . Despite the very small difference in these analogues due to the stereochemistry of the spacers the biological distribution differed significantly in terms of accumulation in the tumour and kidney retention. In order to fully understand the mechanisms responsible for these differences, the authors emphasize the need for further studies on the influence of radiotracer's secondary structure on its pharmacokinetics.
Affinity of the chelator-peptide conjugates to the cell membrane receptors may also vary depending on the metal incorporated into the complex. This phenomenon has been observed both in vitro and in vivo for the radiocomplexes of DOTA conjugated somatostatin and bombesin analogues [11] [12] [13] . It is supposed that the reason for the differentiation of receptor affinity to the respective receptors is in the changes of structure of chelating system and their influence on the bioactive conformations of the metal conjugated peptides [14] . However, stability of the metal complexes may be an additional factor that influences the affinity to the receptors [15] . So far, there are no such studies for the ligands of gastrin/cholecystokinin receptor CCK2R.
In line with the above need, the aim of our project was to investigate the influence of selected metals on the structure and properties of DOTA-(DGlu) 6 -Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH 2 (CP04), a gastrin/CCK analogue. Herein, we report on the radiolabelling of CP04 with 90 Y,
177
Lu and 68 Ga, the synthesis of cold CP04 complexes with respective stable metals, and on their preliminary characterisation by HPLC and LC-MS methods. In (Mallinckrodt) was added to 20 µg of CP04 (Pichem, Austria) dissolved in 0.2 mL of ascorbic acid buffer (50 mg/mL, pH 4.5) and incubated in the microwave oven (Initiator, Biotage) for 5 min or in thermo-block at 95°C for 12 min.
Materials and methods

Optimization
Radiolabelling of CP04 with 68
Ga 200 µL of 68 Ga eluate (200 MBq) from 68 Ge/ 68 Ga generator (iThemba) was added to 20 µL of CP04 (1 mg/mL) and 70 µL of 2.5 M CH 3 COONa, followed by 12 min incubation at 95°C. It was then diluted with 710 µL of ascorbic acid (50 mg/mL, pH 4.5).
Synthesis of the cold complexes of CP04 with Ga, Lu and Y for LC-MS study
The non-radioactive complexes of CP04 with Lu, Y, In and Ga were synthesized in milligram amounts starting from 0.5 mg up to 5 mg of peptide dissolved in ascorbic acid buffer (50 mg/mL, pH 4.5) using 2-fold molar excess of the metal ion. Incubation was carried out for 5 min in microwave oven or 15 min in thermo-block at 95 o C followed by purification on SPE C18 columns. 
Original
Determination of partition coefficient (log P)
For the determination of octanol/water partition coefficients, the aliquots (50 µL) of radiolabelled CP04 complexes were diluted with PBS (pH 7.4) to 500 µL and added to 500 µL of octanol in a testing tube, each in six replicates. The mixture was vigorously vortexed over a period of 15 min at room temperature (RT). After centrifugation, the radioactivity of 50 µL aliquots of both layers was measured in an automatic gamma counter (1470 Wizard, Wallac) and the log P value was calculated.
Analytical method
RP-HPLC isocratic method (Kinetex 150/4.6 mm; 25% AcN/0.1% TFA, 1 mL/min; oven temp. 40°C) with UV/Vis and radiometric detection was devised for investigation of the radiolabelled and "cold" CP04 complexes.
LC-MS study
LC-MS investigations were performed using the UFLC Shimadzu (Kioto, KYT, Japan) system coupled with ABI 4000 QTRAP linear ion trap quadrupole LC/MS/MS mass spectrometer (AB Sciex, Foster City, CA).
Analysis parameters: Kinetex 5u C18 100A, 4.6 × 150 mm column; 25%AcN/0.1% TFA (in some experiments TFA was replaced with formic acid); flow rate 1 mL/min; t = 30°C; ionization electrospray (ESI)/positive; ion spray voltage, 5.5 kV; desolvatation temperature, 700°C; curtain gas, 10 psi. Optimal spectra were obtained from Enhanced MS (EMS) scans at low (40V) declustering potential.
Results and discussion
A macrocyclic chelator DOTA (1,4,7,10-tetraazocyclododecane-1,4,7,10-tetraacetic acid) is one of the most often used chelators for coupling to peptides for PRRT (peptide receptor radionuclide therapy) [16, 17] , however the reaction kinetics differ for each radiometal. Hence, depending on whether the 90 Y, 111 In or 177 Lu are planned to be used, the optimization of radiolabelling conditions is required. In addition, the elevated temperature and incubation time may influence the rate of undesired radiochemical species formation. Contrary to traditional heating devices used for radiolabelling, the microwave heating assures that desired temperatures are reached rapidly in a fully controlled radiolabelling process. Thus, microwave heating shortens incubation time, which might be critical in case of oxidation-sensitive peptides.
Methionine present in the amino acid sequence of CP04 peptide might be oxidised during labelling at elevated temperature, resulting in reduced receptor affinity. Therefore control of oxidation was critical for the quality of potential CP04 based radiopharmaceutical. The microwave oven used in our experiments (Initiator, Biotage) allowed precise control of heating temperature with an infrared sensor. Already after 5 min incubation in the microwave oven at 95 o C the radiolabelling yield greater than 99% (calculated in reference to unbound 90 Y radioactivity) was obtained. The isocratic HPLC method with Kinetex 5u C18 column provided good resolution and allowed the quantitation of observed peaks. The peaks revealed in the radiochromatograms could be attributed to radiolabelled CP04 and to the impurities such as a free radiometal and oxidized form of CP04 due to the methionine oxidation. Radiochemical purity of 90 Y-CP04 depended on the time of incubation and was decreasing with increase of incubation time (Table 1) . At 5, 15 and 25 min incubation the radiochemical purity was 94.4%, 92% and 89.6%, respectively, while the contribution of radioactive oxidized forms of CP04 (Rt ca. 3.5-3.8 min) increased (from 1.2% to 5.8% after 5 and 25 min, respectively). Therefore, for further studies we kept the incubation time as short as possible to obtain 90 Y-DOTA-gastrin of high RCP and to avoid of the methionine residue oxidation.
Cold complexes of CP04 with Y, Lu and Ga were synthesized in sufficient quantities to allow their stability and LC-MS studies. Radiometal complexes of CP04 with 90 Y,
177
Lu and 68 Ga were obtained with yields greater than 90% and their identity was confirmed by HPLC in comparison to their non-radioactive equivalents. In all cases, HPLC chromatograms revealed peaks that could be attributed to the metal-CP04 complexes and to the impurities (including complexes with the oxidized peptide, Rt ca. 2.3-2.9 min). Different chromatographic behaviour observed for Ga-complex comparing to Lu-and Y-CP04 (relative retention to CP04: 1.08, 0.86 and 0.85, respectively) suggests different coordination of the metal ions (Fig. 2) . The partition coefficient Log P values of −2.92 ± 0.005 were determined for 90 Y-CP04 as well as for 177 Lu-CP04 while it was −2.68 ± 0.03 for LC-MS analysis of Ga and Lu complexes revealed conformity of the observed molecular ions to the predicted formulas (m/z 2116 Table 2 ). In the Ga complex only 2 carboxylic groups of DOTA are involved in the coordination, whereas 3 carboxylic groups are needed for Lu, Y and In. This results in different geometry of complexes with CP04. Our observations are in accordance with those by Viola-Villegas et al. [18] , who proposed different structures for Ga-and Lu/Y-DOTA complexes.
Conclusions
Our study showed that the DOTA conjugated minigastrin analogue, CP04, can be easily and efficiently radiolabelled both with positron emitting radionuclide 68 Ga, as well as with beta minus emitting radionuclides such as yttrium-90 or lutetium-177. However, different coordination of radiometals may lead to different physico-chemical and biological properties of these radiocomplexes. LC-MS study revealed that in case of yttrium and lutetium complexes, 3 carboxylic groups of DOTA are involved in the radiometal coordination, whereas in case of gallium only 2. This structural difference causes differential hydrophilicity of the Gaand Y/Lu-complexes what has been observed in chromatographic and partition coefficient studies.
Further in vitro and in vivo studies are in progress to indicate whether the type of coordination of radiometal by DOTA bifunctional chelator significantly influences the biological properties of radiolabelled CP04 and its interaction with CCK-2 receptors in vivo.
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